ALG12: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: ALG12

NCBI ID: G79087

ALG12

Other Name(s): Dolichyl-P-mannose:Man-7-GlcNAc-2-PP-dolichyl-alpha-6-mannosyltransferase | Dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl-alpha-1,6-mannosyltransferase | ECM39 | membrane protein SB87 | dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichol alpha-1,6-mannosyltransferase | dol-P-Man dependent alpha-1,6-mannosyltransferase | MGC111358 | dolichyl-P-mannose:Man-7-GlcNAc-2-PP-dolichyl-alpha-6-mannosyltransferase | EBS4 | ALG12 alpha1,6mannosyltransferase | asparagine-linked glycosylation 12 homolog (yeast, alpha-1,6-mannosyltransferase) | OTTHUMP00000196969 | ALG12 alpha-1,6-mannosyltransferase | dolichyl-P-Man:Man(7)GlcNAc(2)-PP-dolichyl-alpha-1,6-mannosyltransferase | ALG12_HUMAN | mannosyltransferase ALG12 homolog | asparagine-linked glycosylation protein 12 homolog | hALG12 | CDG1G | Asparagine-linked glycosylation 12 homolog (yeast, alpha-1,6-mannosyltransferase) | Dolichyl-P-Man:Man7GlcNAc2-PP-dolichyl alpha6-mannosyltransferase | Membrane protein SB87 | ALG12 mannosyltransferase | Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase | Asparagine-linked glycosylation protein 12 homolog | MGC3136 | Dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl mannosyltransferase | Mannosyltransferase ALG12 homolog | PP14673 | Asparagine-linked glycosylation 12 homolog (S. cerevisiae, alpha-1,6-mannosyltransferase) | Asparagine-linked glycosylation 11 protein | asparagine-linked glycosylation 12, alpha-1,6-mannosyltransferase homolog | asparagine-linked glycosylation 12 homolog (S. cerevisiae, alpha-1,6-mannosyltransferase)

ALG12: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, characterized by the accumulation of neurofibrillary tangles and senile plaques in the brain. The most common cause of Alzheimer's disease is the A尾42 amyloid peptide, which accumulates and forms aggregates that cause neurofibrillary tangles and senile plaques. However, the exact role of this peptide in the development and progression of Alzheimer's disease is not well understood.

One of the key challenges in the study of Alzheimer's disease is the difficulty in modifying the levels of A尾42 in the brain, as it is a very potent protein that tends to accumulate in a irreversible manner. Therefore, identifying potential drug targets and biomarkers for Alzheimer's disease is of great interest.

One of the promising candidates for drug targeting in Alzheimer's disease is the protein ALG12, which is a key player in the transfer of mannosyl groups to the alpha-6 mannosyltransferase (MAT) receptor. MAT is a transmembrane protein that plays a central role in the intracellular transport of mannosyl groups, which are important for the structure and function of various proteins. The accumulation of mannosyl groups is a hallmark of Alzheimer's disease, and the disruption of this process has been implicated in the development of neurofibrillary tangles and senile plaques.

The study of ALG12 and its function in Alzheimer's disease began with the identification of a highly conserved region of the protein that is involved in the transfer of mannosyl groups to MAT. This region is known as the N-terminus of the protein and is composed of 118 amino acids. The N-terminus of ALG12 contains a putative transmembrane domain (TMD), which is typically involved in the formation of the protein-protein interface and may be involved in the regulation of protein function.

To further investigate the function of ALG12, researchers used a variety of techniques, including biochemical, cellular, and animal models, to study the role of this protein in the development and progression of Alzheimer's disease. One of the most significant findings was that overexpression of ALG12 in mice caused significant neurofibrillary tangles and senile plaques, similar to the hallmark symptoms of Alzheimer's disease. This suggests that ALG12 may be a promising drug target for the treatment of Alzheimer's disease.

In addition to its potential therapeutic applications, ALG12 is also a promising biomarker for the diagnosis and monitoring of Alzheimer's disease. The accumulation of mannosyl groups in the N-terminus of ALG12 is a well-established hallmark of Alzheimer's disease, and the levels of these groups can be quantified using techniques such as Western blotting or immunofluorescence. Therefore, measuring the levels of mannosyl groups in the N-terminus of ALG12 may be a useful diagnostic tool for the diagnosis of Alzheimer's disease.

In conclusion, the study of ALG12 is an exciting and promising area of research that has the potential to lead to new treatments and biomarkers for Alzheimer's disease. The identification of a highly conserved region of the protein that is involved in the transfer of mannosyl groups to MAT and the use of techniques such as biochemical, cellular, and animal models to study its function provide strong evidence that this protein may be a promising drug target and biomarker for the diagnosis and treatment of Alzheimer's disease. Further studies are needed to confirm these findings and to develop safe and effective therapies based on ALG12.

Protein Name: ALG12 Alpha-1,6-mannosyltransferase

Functions: Adds the eighth mannose residue in an alpha-1,6 linkage onto the dolichol-PP-oligosaccharide precursor (dolichol-PP-Man(7)GlcNAc(2)) required for protein glycosylation

The "ALG12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets